On the significance of the trigger reaction in the action of the calicheamicin γI1 anti-cancer drug

被引:29
|
作者
Lindh R. [1 ]
Ryde U. [1 ]
Schütz M. [1 ]
机构
[1] Theoretical Chemistry, Chemical Center, S-221 00 Lund
关键词
Bergman reaction; Calicheamicin; Integral-direct MP2; Parallel MP2; Trigger reaction;
D O I
10.1007/s002140050254
中图分类号
学科分类号
摘要
The significance of the so-called trigger reaction in the reaction mechanism of the calicheamicin γI1 anti-cancer drug has been studied with ab initio quantum chemical methods. The structures of four fragments of calicheamicin γI1, consisting of either 39 or 41 atoms, have been fully optimized using the Becke-Perdew86 density functional method and the 6-31G* basis sets. The four structures constitute members of an isodesmic reaction for which the reaction energy is a direct measure of the change in activation energy of the Bergman reaction, caused by the structural rearrangements of the preceding trigger reaction. This difference in activation energy has been calculated with density functional theory, using the exchange-correlation functional mentioned above, and with second-order Møller-Plesset perturbation theory (MP2), employing an ANO-type basis set. In both cases a value of 12 kcal/ mol is obtained. The study firmly supports the hypothesis that the significance of the trigger reaction is to saturate a double bond in the vicinity of the enediyne group, which counteracts the formation of the biradical state of the drug. The MP2 computations became feasible by a novel implementation of an integral-direct, distributed-data, parallel MP2 algorithm.
引用
收藏
页码:203 / 210
页数:7
相关论文
共 50 条
  • [1] On the significance of the trigger reaction in the action of the calicheamicin gamma(I)(1) anti-cancer drug
    Lindh, R
    Ryde, U
    Schutz, M
    THEORETICAL CHEMISTRY ACCOUNTS, 1997, 97 (1-4) : 203 - 210
  • [2] Transcriptional effects of the potent enediyne anti-cancer agent calicheamicin γ
    Watanabe, CMH
    Supekova, L
    Schultz, PG
    CHEMISTRY & BIOLOGY, 2002, 9 (02): : 245 - 251
  • [3] ANTI-CANCER ACTION OF RETINOIDS
    MEDAWAR, PB
    HUNT, R
    IMMUNOLOGY, 1981, 42 (02) : 349 - 353
  • [4] Anti-cancer drug - Preface
    Bergmann-Leitner, ES
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (19)
  • [5] STUDIES OF THE MECHANISM OF ACTION OF CIS-DICHLORODIAMMINEPLATINUM(II), AN ANTI-CANCER DRUG
    BAUER, WR
    LIPPARD, SJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1980, 179 (MAR): : 25 - MEDI
  • [6] LncRNA UCA1 in anti-cancer drug resistance
    Wang, Haohao
    Guan, Zhonghai
    He, Kuifeng
    Qian, Jiong
    Cao, Jiang
    Teng, Lisong
    ONCOTARGET, 2017, 8 (38) : 64638 - 64650
  • [7] Current Development of Anti-Cancer Drug S-1
    Chhetri, Pratima
    Giri, Anil
    Shakya, Suraj
    Shakya, Sujana
    Sapkota, Binaya
    Pramod, K. C.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016, 10 (11) : XE1 - XE5
  • [8] Anti-Cancer Drug Delivery System
    Li Yan
    Huang Wei
    Huang Ping
    Zhu Xinyuan
    Yan Deyue
    PROGRESS IN CHEMISTRY, 2014, 26 (08) : 1395 - 1408
  • [9] Valproic acid as anti-cancer drug
    Michaelis, Martin
    Doerr, Hans Wilhelm
    Cinatl, Jindrich, Jr.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (33) : 3378 - 3393
  • [10] MACROMOLECULE ANTI-CANCER DRUG CONJUGATES
    KATO, Y
    HARA, T
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 1983, 41 (12) : 1135 - 1142